Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Sign Up to like & getrecommendations! Published in 2018 at "Trends in pharmacological sciences"
DOI: 10.1016/j.tips.2017.11.007
Abstract: Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) catalyze the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the immunosuppressive effect of IDO1 has been attributed mainly to reduced levels of tryptophan, which… read more here.
Keywords: tdo2; tdo2 kyn; targeting ido1; cancer ... See more keywords